Ascletis Pharma Inc. (2VJ.F)
Ascletis Pharma Inc.
Building D
12th Floor 198 Qidi Road, HIPARK Xiaoshan District
Hangzhou 311200
China
86 571 8538 9730
https://www.ascletis.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 219
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jinzi Jason Wu Ph.D. | Founder, Chairman & CEO | 7.41M | N/D | 1964 |
| Ms. Hejingdao Wu | Senior VP of Operations & Executive Director | 366.65k | N/D | 1974 |
| Ms. Yuemei Yan | Senior Vice President of Clinical Development Operations | N/D | N/D | 1970 |
| Dr. Kristjan Sigurdur Gudmundsson | Senior Consultant & Head of Discovery | N/D | N/D | 1968 |
| Dr. George Zhengzhi Hill | Senior Consultant & Chief Medical Advisor | N/D | N/D | 1951 |
| Mr. John P. Gargiulo M.B.A. | Chief Business Officer | N/D | N/D | 1960 |
| Mr. Ming Fai Chung C.P.A. | Company Secretary | N/D | N/D | 1979 |
Descripción
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
Gestión corporativa
La calificación ISS Governance QuickScore de Ascletis Pharma Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
